C
Codexis
Biosciences company applying synthetic chemistry technologies to create improved versions of small molecule therapeutics
At a glance
- Status
- Listed
- Founded
- 2002
- Headquarters
- Redwood City, United States
- Listing
- IPO 2010
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
- MAMaxygen
- CVChevron Technology Ventures
- BCBio*One Capital
- EDEDBI
- CCCMEA Capital
Source: Dealroom Talent Intelligence.
Alumni founders
Former Codexis employees who went on to found companies, sorted by Dealroom signal score.
ZFZero Acre FarmsEst. 2020
Stephen Del CardayreUnited States
ACAcepodiaEst. 2016
YOYodo1Est. 2012
James LalondeChina
PRProviviEst. 2013
Frances ArnoldUnited StatesGlobal footprint
team presence
across markets
Patents
222 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Codexis was the backer or acquirer, 2021–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Codexis's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Codexis's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Codexis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Codexis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.